Role of VEGF-C gene polymorphisms in susceptibility to hepatocellular carcinoma and its pathological development

Journal of Clinical Laboratory Analysis

Volumn 28, Issue 3, 2014, Pages 237-244

  Hsieh, Ming Chang ^a,b   Hsu, Hui Ting ^a,c,d   Hsiao, Pei Ching ^a   Yang, Shun Fa ^a,b   Yeh, Chao Bin ^a,b   Bien, Mauo Ying ^e   Lin, Chien Huang ^f   Chien, Ming Hsien ^f,g  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Single nucleotide polymorphism; Vascular endothelial growth factor C

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VASCULOTROPIN C;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HAPLOTYPE; HOMOZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INTRON; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TOBACCO CONSUMPTION; TUMOR VOLUME; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84899620962     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21672     Document Type: Article

References (36)

1. Shastry BS. SNP alleles in human disease and evolution. J Hum Genet 2002;47(11):561-566.
2. Wu CS, Yen CJ, Chou RH, et al. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. PLoS One 2012;7(7):e39466.
3. Chien MH, Yeh CB, Li YC, et al. Relationship of interleukin-8 gene polymorphisms with hepatocellular carcinoma susceptibility and pathological development. J Surg Oncol 2011;104(7):798-803.
4. Yano Y, Yamashita F, Kuwaki K, et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 2006;26(7):789-795.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6(9):674-687.
6. Firpi RJ, Nelson DR. Viral hepatitis: Manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006;2006(1):375-380.
7. Feitelson MA. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett 2006;239(1):10-20.
8. Hsieh YS, Tsai CM, Yeh CB, Yang SF, Hsieh YH, Weng CJ. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol 2012;19(3): S625-S633.
9. Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010;17(7):1808-1815.
10. Chung TT, Yeh CB, Li YC, et al. Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. PLoS One 2012;7(3):e33517.
11. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31(4):339-346.
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-676.
13. Orlandini M, Spreafico A, Bardelli M, et al. Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. J Biol Chem 2006;281(26):17961-17967.
14. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 2010;17(4):253-261.
15. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007;67(2):593-599.
16. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454(7204):656-660.
17. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006;9(3):209-223.
18. Kodama M, Kitadai Y, Tanaka M, et al. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 2008;14(22):7205-7214.
19. Yamaguchi R, Yano H, Nakashima O, et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21(1 Pt 1):152-160.
20. Marchio S, Primo L, Pagano M, et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 1999;274(39):27617-27622.
21. Goode EL, Maurer MJ, Sellers TA, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010;16(3):995-1007.
22. Yu YL, Su KJ, Chen CJ, et al., Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells. J Cell Physiol 2012;227: 213-222.
23. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12(9-10):S294-S308.
24. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10(3):185-200.
25. Srinivas SK, Morrison AC, Andrela CM, Elovitz MA. Allelic variations in angiogenic pathway genes are associated with preeclampsia. Am J Obstet Gynecol 2010;202(5):e1-e11.
26. Hong JM, Kim TH, Kim HJ, Park EK, Yang EK, Kim SY. Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med 2010;42(5):376-385.
27. Serre D, Gurd S, Ge B, et al. Differential allelic expression in the human genome: A robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet 2008;4(2):e1000006.
28. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11(4):274-286.
29. Tsukada S, Tanaka Y, Maegawa H, Kashiwagi A, Kawamori R, Maeda S. Intronic polymorphisms within TFAP2B regulate transcriptional activity and affect adipocytokine gene expression in differentiated adipocytes. Mol Endocrinol 2006;20(5):1104-1111.
30. Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kulikowski M, Niklinski J. Serum levels of VEGF and VEGF-C in patients with endometrial cancer. Eur Cytokine Netw 2011;22(1):45-51.
31. Li QL, Chen FJ, Zeng ZY, et al. [Expression and clinical significance of VEGF-C and Flt-4 in tongue squamous cell carcinoma]. Ai Zheng 2006;25(2):235-240.
32. Xiang ZL, Zeng ZC, Tang ZY, et al. [Nuclear accumulation of CXCR4 and overexpressions of VEGF-C and CK19 are associated with a higher risk of lymph node metastasis in hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 2010;32(5):344-349.
33. Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012;31:1389-1397.
34. Fairbrother WG, Chasin LA. Human genomic sequences that inhibit splicing. Mol Cell Biol 2000;20(18):6816-6825.
35. Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB. Systematic identification and analysis of exonic splicing silencers. Cell 2004;119(6):831-845.
36. Wagner EJ, Garcia-Blanco MA. Polypyrimidine tract binding protein antagonizes exon definition. Mol Cell Biol 2001;21(10):3281-3288.